Aldosterone and blood pressure regulation: Recent milestones on the long and winding road from electrocortin to KCNJ5, GPER, and beyond

Hypertension

Volumn 63, Issue 1, 2014, Pages 19-21

  Feldman, Ross D ^a  

^a WESTERN UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ALDOSTERONE ANTAGONIST; POTASSIUM ION;

ARTICLE; BLOOD PRESSURE REGULATION; HUMAN; HYPERALDOSTERONISM; HYPERTENSION; ION CURRENT; PRIORITY JOURNAL; RESISTANT HYPERTENSION;

ALDOSTERONE; BLOOD PRESSURE; CARDIOVASCULAR SYSTEM; G PROTEIN-COUPLED INWARDLY-RECTIFYING POTASSIUM CHANNELS; HUMANS; HYPERALDOSTERONISM; HYPERTENSION; POTASSIUM; RECEPTORS, ESTROGEN; RECEPTORS, G-PROTEIN-COUPLED;

EID: 84891631637     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.113.01251     Document Type: Article

References (29)

1. Gross F, Gysel H. The action of electrocortin in the adrenalectomized dog. Acta Endocrinol (Copenh). 1954;15:199-209
2. Feldman RD, Gros R. Vascular effects of aldosterone: Sorting out the receptors and the ligands. Clin Exp Pharmacol Physiol. 2013. doi: 10.1111/1440-1681.12157
3. Funder JW. The nongenomic actions of aldosterone. Endocr Rev. 2005;26:313-321
4. Grossmann C, Benesic A, Krug AW, Freudinger R, Mildenberger S, Gassner B, Gekle M. Human mineralocorticoid receptor expression renders cells responsive for nongenotropic aldosterone actions. Mol Endocrinol. 2005;19:1697-1710
5. Wendler A, Baldi E, Harvey BJ, Nadal A, Norman A, Wehling M. Position paper: Rapid responses to steroids: Current status and future prospects. Eur J Endocrinol. 2010;162:825-830
6. McCurley A, Pires PW, Bender SB, Aronovitz M, Zhao MJ, Metzger D, Chambon P, Hill MA, Dorrance AM, Mendelsohn ME, Jaffe IZ. Direct regulation of blood pressure by smooth muscle cell mineralocorticoid receptors. Nat Med. 2012;18:1429-1433
7. Filardo EJ, Thomas P. Minireview: G protein-coupled estrogen receptor-1, GPER-1: Its mechanism of action and role in female reproductive cancer, renal and vascular physiology. Endocrinology. 2012;153:2953-2962
8. Gros R, Ding Q, Liu B, Chorazyczewski J, Feldman RD. Aldosterone mediates its rapid effects in vascular endothelial cells through GPER activation. Am J Physiol Cell Physiol. 2013;304:C532-C540
9. Gros R, Ding Q, Sklar LA, Prossnitz EE, Arterburn JB, Chorazyczewski J, Feldman RD. GPR30 expression is required for the mineralocorticoid receptor-independent rapid vascular effects of aldosterone. Hypertension. 2011;57:442-451
10. Lindsey SH, Carver KA, Prossnitz ER, Chappell MC. Vasodilation in response to the GPR30 agonist G-1 is not different from estradiol in the mRen2.Lewis female rat. J Cardiovasc Pharmacol. 2011;57:598-603
11. Batenburg WW, Jansen PM, van den Bogaerdt AJ, J Danser AH. Angiotensin II-aldosterone interaction in human coronary microarteries involves GPR30, EGFR, and endothelial NO synthase. Cardiovasc Res. 2012;94:136-143
12. Brailoiu GC, Benamar K, Arterburn JB, Gao E, Rabinowitz JE, Koch WJ, Brailoiu E. Aldosterone increases cardiac vagal tone via GPER activation. J Physiol. 2013;591:4223-4235
13. Stowasser M. Primary aldosteronism in 2011: Towards a better understanding of causation and consequences. Nat Rev Endocrinol. 2012;8:70-72
14. Zennaro MC, Rickard AJ, Boulkroun S. Genetics of mineralocorticoid excess: An update for clinicians. Eur J Endocrinol. 2013;169:R15-R25
15. Lifton RP, Dluhy RG, Powers M, Rich GM, Cook S, Ulick S, Lalouel JM. A chimaeric 11 beta-hydroxylase/aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension. Nature. 1992;355:262-265
16. Robertson S, Mackenzie SM, Alvarez-Madrazo S, Diver LA, Lin J, Stewart PM, Fraser R, Connell JM, Davies E. MicroRNA-24 is a novel regulator of aldosterone and cortisol production in the human adrenal cortex. Hypertension. 2013;62:572-578
17. Choi M, Scholl UI, Yue P, et al. K+ channel mutations in adrenal aldosteroneproducing adenomas and hereditary hypertension. Science. 2011;331:768-772
18. Azizan EA, Murthy M, Stowasser M, Gordon R, Kowalski B, Xu S, Brown MJ, O'Shaughnessy KM. Somatic mutations affecting the selectivity filter of KCNJ5 are frequent in 2 large unselected collections of adrenal aldosteronomas. Hypertension. 2012;59:587-591
19. Boulkroun S, Beuschlein F, Rossi GP, et al. Prevalence, clinical, and molecular correlates of KCNJ5 mutations in primary aldosteronism. Hypertension. 2012;59:592-598
20. Mulatero P, Tauber P, Zennaro MC, et al. KCNJ5 mutations in European families with nonglucocorticoid remediable familial hyperaldosteronism. Hypertension. 2012;59:235-240
21. Calhoun DA. Hyperaldosteronism as a common cause of resistant hypertension. Annu Rev Med. 2013;64:233-247
22. Sartori M, Calò LA, Mascagna V, Realdi A, Macchini L, Ciccariello L, De Toni R, Cattelan F, Pessina AC, Semplicini A. Aldosterone and refractory hypertension: A prospective cohort study. Am J Hypertens. 2006;19:373-380
23. Ogilvie RI, Piafsky KM, Ruedy J. Antihypertensive responses to spironolactone in normal renin hypertension. Clin Pharmacol Ther. 1978;24:525-530
24. Ouzan J, Pérault C, Lincoff AM, Carré E, Mertes M. The role of spironolactone in the treatment of patients with refractory hypertension. Am J Hypertens. 2002;15(4 Pt 1):333-339
25. de Souza F, Muxfeldt E, Fiszman R, Salles G. Efficacy of spironolactone therapy in patients with true resistant hypertension. Hypertension. 2010;55:147-152
26. Wray DW, Supiano MA. Impact of aldosterone receptor blockade compared with thiazide therapy on sympathetic nervous system function in geriatric hypertension. Hypertension. 2010;55:1217-1223
27. Raheja P, Price A, Wang Z, Arbique D, Adams-Huet B, Auchus RJ, Vongpatanasin W. Spironolactone prevents chlorthalidone-induced sympathetic activation and insulin resistance in hypertensive patients. Hypertension. 2012;60:319-325
28. Xue B, Zhang Z, Roncari CF, Guo F, Johnson AK. Aldosterone acting through the central nervous system sensitizes angiotensin II-induced hypertension. Hypertension. 2012;60:1023-1030
29. Xue B, Beltz TG, Yu Y, Guo F, Gomez-Sanchez CE, Hay M, Johnson AK. Central interactions of aldosterone and angiotensin II in aldosterone-and angiotensin II-induced hypertension. Am J Physiol Heart Circ Physiol. 2011;300:H555-H564